Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Lessened by Toronto Dominion Bank

Toronto Dominion Bank lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 32.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,336 shares of the medical research company's stock after selling 8,281 shares during the period. Toronto Dominion Bank's holdings in Charles River Laboratories International were worth $3,200,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of CRL. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $37,000. GeoWealth Management LLC raised its stake in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $48,000. Tortoise Investment Management LLC lifted its position in shares of Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the last quarter. Finally, Huntington National Bank grew its stake in Charles River Laboratories International by 120.6% in the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on CRL. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Finally, Barclays raised their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded up $4.83 during mid-day trading on Wednesday, hitting $143.32. 849,402 shares of the company's stock traded hands, compared to its average volume of 995,086. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The firm has a 50 day moving average price of $127.93 and a 200 day moving average price of $159.55. The company has a market cap of $7.04 billion, a PE ratio of 955.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period last year, the firm posted $2.27 earnings per share. The business's revenue was down 2.7% on a year-over-year basis. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).